Drug side effects linked to reduced recurrence of melanoma
Immune-related adverse events with pembrolizumab ‘reflects drug activity’.
Immune-related adverse events with pembrolizumab ‘reflects drug activity’.
A meta-analysis suggests the treatment is safe but there is only 'low quality' evidence.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.